{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T23:53:47Z","timestamp":1787270027020,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>\n                    This network meta-analysis evaluated the efficacy and safety of the dextromethorphan\u2013bupropion combination (AXS-05) in treating major depressive disorder (MDD). Data were retrieved from multiple databases, including PubMed, Embase, Scopus, Google Scholar, and ClinicalKey, yielding 60 records. After removing duplicates and excluding irrelevant studies, such as reviews, case reports, posters, and studies focusing on unrelated populations (e.g., Alzheimer\u2019s dementia), two randomized controlled trials (RCTs) \u2013 Tabuteau\n                    <jats:italic toggle=\"yes\">et al<\/jats:italic>\n                    . (2022) and Iosifescu\n                    <jats:italic toggle=\"yes\">et al<\/jats:italic>\n                    . (2022) \u2013 were selected for final analysis. The inclusion criteria focused on RCTs published between 2014 and 2024, involving adult participants (18\u201365 years) diagnosed with MDD, and reporting on the efficacy and safety of the dextromethorphan\u2013bupropion combination. Studies that did not focus on MDD, were not in English, or lacked control groups were excluded. The findings indicate superior efficacy of the dextromethorphan\u2013bupropion combination, with remission rates of 46.5% and 39.5%, compared to 16.2% for Bupropion alone and 17.3% for placebo. Despite a higher incidence of mild to moderate adverse events (72.9% vs. 64.6% for Bupropion), the combination\u2019s safety profile remained comparable, with no significant increase in treatment discontinuation. These results suggest that AXS-05 is a promising treatment for MDD, warranting further investigation in larger, diverse populations to confirm its long-term efficacy and safety.\n                  <\/jats:p>","DOI":"10.4103\/ijp.ijp_907_24","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T11:00:17Z","timestamp":1753095617000},"page":"262-268","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of dextromethorphan\u2013bupropion combination (AXS-05) in the treatment of depression: A systematic review and network meta-analysis"],"prefix":"10.4103","volume":"57","author":[{"given":"JV","family":"Ashwin","sequence":"first","affiliation":[{"name":"Department of Geriatric Mental Health, KGMU, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit Kumar","family":"Shahi","sequence":"additional","affiliation":[{"name":"Department of Geriatric Mental Health, KGMU, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astha","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Hind Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Theepan","family":"Kumar","sequence":"additional","affiliation":[{"name":"Community Medicine, KGMU, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"1","DOI":"10.24191\/jchs.v3i1.6150","article-title":"The burden of mental illness: An emerging global disaster","volume":"3","author":"Salleh","year":"2018","journal-title":"J Clin Health Sci"},{"key":"R4-20260422","first-page":"e46145","article-title":"Effects of mental illness amongst adults in the United States living with diabetes mellitus on hospital admissions","volume":"15","author":"Gettas","year":"2023","journal-title":"Cureus"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/070674371506000104","article-title":"The STAR*D trial: It is time to reexamine the clinical beliefs that guide the treatment of major depression","volume":"60","author":"Pigott","year":"2015","journal-title":"Can J Psychiatry"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"21m14345","DOI":"10.4088\/JCP.21m14345","article-title":"Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI)","volume":"83","author":"Iosifescu","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"609","DOI":"10.9758\/cpn.23.1081","article-title":"Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder","volume":"21","author":"McCarthy","year":"2023","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/acs.jmedchem.1c00028","article-title":"Novel approaches, drug candidates, and targets in pain drug discovery","volume":"64","author":"Obeng","year":"2021","journal-title":"J Med Chem"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1177\/0091270004269521","article-title":"Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers","volume":"44","author":"Pope","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2174\/1574885519666230913105725","article-title":"Auvelity: A new era in medicine-unraveling the multifaceted benefits of dextromethorphan\/bupropion combination","volume":"19","author":"Dhawan","year":"2024","journal-title":"Curr Drug Ther"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nurt.2008.10.039","article-title":"Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: Novel concepts, new drugs","volume":"6","author":"Millan","year":"2009","journal-title":"Neurotherapeutics"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jclinepi.2020.07.005","article-title":"Using the full PICO model as a search tool for systematic reviews resulted in lower recall for some PICO elements","volume":"127","author":"Frandsen","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"R13-20260422","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1176\/appi.ajp.21080800","article-title":"Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: A randomized double-blind controlled trial","volume":"179","author":"Tabuteau","year":"2022","journal-title":"Am J Psychiatry"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euroneuro.2024.04.016","article-title":"Network meta-analysis (NMA) of dextromethorphan-bupropion (AXS-05) efficacy and safety in major depressive disorder","volume":"86","author":"Gaca","year":"2024","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_907_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:27:19Z","timestamp":1786735639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_907_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_907_24","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-10-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}